Guy Meyer

TL;DR: Among hospitalized patients with severe acute pulmonary embolism, the use of a retrievable inferior vena cava filter plus anticoagulation compared with anticogulation alone did not reduce the risk of symptomatic recurrent pulmonary emblism at 3 months, and these findings do not support theUse of this type of filter in patients who can be treated with antICOagulation.

TL;DR: The accuracy of tests for suspected pulmonary emblism varies greatly, but it is possible to estimate the range of pretest probabilities over which each test or strategy can confirm or rule out pulmonary embolism.

TL;DR: Several demographic, geographic, and clinical factors are independent risk factors for VTE and early mortality in patients with lung cancer receiving systemic chemotherapy, and the Khorana risk score is of value in assessing the risk of early all-cause mortality.

TL;DR: A PE prevalence in COVID-19 patients is suggested close to 5% in the whole population and to 20% of the clinically suspected population, which seems to be associated with more extensive lung damage and to require more frequently invasive ventilation.

TL;DR: In this paper, a randomized open-label non-inferiority trial was conducted to evaluate the effectiveness of direct oral anticoagulants (DOACs) compared to low-molecular-weight heparin for treating cancer-associated venous thromboembolism (VTE).